There are currently 4 active clinical trials seeking participants for Hereditary Angioedema (HAE) research studies. The states with the highest number of trials for Hereditary Angioedema (HAE) participants are California, Ohio, Texas and Pennsylvania.
A Phase 2 in Adult Subjects With Hereditary Angioedema
Recruiting
A Phase 2 in Adult Subjects with Hereditary Angioedema
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/25/2025
Locations: Raffi Tachdjian, MD Inc, Santa Monica, California +18 locations
Conditions: Hereditary Angioedema (HAE)
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/23/2025
Locations: Study Site, Little Rock, Arkansas +44 locations
Conditions: Hereditary Angioedema (HAE)
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Recruiting
This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/23/2025
Locations: Study Site, Santa Monica, California +14 locations
Conditions: Hereditary Angioedema (HAE)
A Study of Navenibart in Participants With Hereditary Angioedema
Recruiting
This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/23/2025
Locations: Site 9, Birmingham, Alabama +13 locations
Conditions: Hereditary Angioedema (HAE)